Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- Clinical management in ATTR-CM is longitudinal, not one treatment decision.
- Ongoing monitoring, treatment adherence, and continuity of care are essential components of long-term management.
- Clinical deterioration should be evaluated carefully to distinguish disease progression from treatment interruption or other contributing factors.
What Clinical Management Means in ATTR-CM
Clinical management of ATTR-CM requires long-term treatment, ongoing assessment of congestion, and regular clinical follow-up. Management decisions should be based on serial clinical assessment over time rather than on findings from a single visit. This longitudinal approach underpins all aspects of ATTR-CM management, from routine follow-up to the care of patients with advanced disease.
Why Continuity Belongs Inside Management
Long-term management includes medication reconciliation, continuity of treatment, assessment of renal function and volume status, rhythm surveillance, and ongoing symptom evaluation. Interruptions in medication access, treatment adherence, or follow-up may adversely affect patient outcomes. Therefore, serial clinical assessment, ongoing evaluation of treatment tolerability, and continuity of care are integral components of ATTR-CM management.
Reading a Worse Month: Progression, Exposure, or Both?
The hardest interpretive problem is often whether a worse month reflects disease progression, inconsistent exposure, or both. When clinical status worsens, clinicians should consider disease progression, treatment interruption, and other contributing factors before modifying therapy. Assessment of treatment adherence and continuity should be part of the evaluation when a patient's clinical status worsens, as interruptions in therapy may contribute to an apparent lack of treatment response and should be excluded before modifying treatment.
Practical Management Checklist
Across visits, treat continuity as part of therapy:
- Has the patient remained continuously on therapy, with refills and access intact?
- Are symptoms, congestion, renal function, and rhythm being assessed serially over time, not single visits?
- When clinical status worsens, has interrupted exposure been excluded before assuming progression?
- Is medication reconciliation current so medication-related issues or interruptions in care are identified and addressed promptly?
Clinical Decision Point
When a patient's clinical status appears to worsen, evaluation should include assessment of disease progression, treatment adherence, and continuity of therapy before changes in treatment are considered. Identifying potentially reversible factors, such as interruptions in treatment access or adherence, may help avoid unnecessary modifications to an otherwise appropriate treatment plan.
Frequently Asked Questions
Why is ATTR-CM management described as longitudinal?
ATTR-CM management is described as longitudinal because the useful unit of care is the course over time, not a single visit. Sustained therapy, congestion control, and serial interpretation matter more than any one decision point.
Why count persistence and access as part of therapy?
Treatment adherence, continuity of medication access, and regular follow-up are essential components of ATTR-CM management because interruptions in care may reduce the effectiveness of otherwise appropriate treatment.
How should a worsening course be interpreted?
A worsening clinical course should be interpreted with caution. A worse month can reflect progression, interrupted exposure, or both. Confirming continuous therapy first and using serial clinical assessment rather than isolated measurements helps separate the two before changing the plan.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Manage the Disease
Next Clinical Decision
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. Journal of Managed Care & Specialty Pharmacy
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.